Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →

Search

Top

UNIVERSITY OF CHICAGO Chicago IL 60637 USA

UEI: SLED_6D7EF4695EA4C76F

UNIVERSITY OF CHICAGO Chicago IL 60637 USA is a federal contractor, registered under UEI SLED_6D7EF4695EA4C76F. It has been awarded $9,807,060 across 1 federal contract. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include National Institutes Of Health Niaid.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_6D7EF4695EA4C76F

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

National Institutes Of Health Niaid$9.8M100%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$9.8M100%

Awards by Agency Over Time

Awards by Place of Performance

Compete with UNIVERSITY OF CHICAGO Chicago IL 60637 USA

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for UNIVERSITY OF CHICAGO Chicago IL 60637 USA

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in UNIVERSITY OF CHICAGO Chicago IL 60637 USA's top NAICS codes and agencies

Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract

Solicitation # HT942627RE002

The Defense Health Agency Contracting Activity intends to issue a Request for Proposal in early November 2026 for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle. This opportunity is specifically set aside for small businesses certified under the Small Business Administration 8(a) Program and will focus on providing military medical research and development services. Multiple new awards are expected, all of which will align with the existing unrestricted contract vehicle. The OMNIBUS IV vehicle operates with a cumulative ceiling of 10 billion dollars and a performance period extending through June 19, 2032, including option years. To date, the contract has seen over 690 million dollars awarded across 61 task orders to various end users, including the Naval Supply Systems Command and the Uniformed Services University of the Health Sciences. Task orders may be competed via fair opportunity or through specific exceptions such as small business set-asides.

Defense Health Agency

POSTED

DEADLINE

Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract

Solicitation # HT942626RE002

The Defense Health Agency Contracting Activity is issuing a pre-solicitation notice for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity (IDIQ) contract vehicle. This initiative aims to expand the pool of eligible contractors providing military medical research and development services, including laboratory and technical support, regulatory process expertise, and translational science services. The eventual Request for Proposal will be set aside exclusively for small businesses certified under the Small Business Administration 8(a) Program. Due to the need to implement recent FAR Overhaul guidance, the anticipated posting timeframe for the solicitation has been extended to late September 2026. The OMNIBUS IV vehicle operates with a base ordering period from June 20, 2022, through June 19, 2027, and an option ordering period extending to June 19, 2032. It features a cumulative ceiling of 10 billion dollars, with over 630 million dollars already awarded across 55 task orders to various end users, including the Naval Supply Systems Command and the Uniformed Services University of the Health Sciences. New awards from this on-ramp will align with the existing unrestricted vehicle. Prospective offerors must be registered in SAM.gov and will be required to submit proposals through the Procurement Integrated Enterprise Environment solicitation module once the formal RFP is released.

Defense Health Agency

POSTED

DEADLINE

Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-031

The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for the Centers for Structural Biology of HIV and Other Infectious Diseases (RFA-AI-28-031). This funding opportunity seeks to establish multidisciplinary consortia of structural biologists and microbiologists to solve complex biological structures necessary for the prevention, treatment, and cure of HIV and other infectious diseases. The program emphasizes the use of advanced experimental approaches, including hybrid imaging, artificial intelligence, protein design, and dynamic computational modeling. NIAID intends to commit 33 million dollars in FY 2028, with individual application budgets not expected to exceed 3.5 million dollars in direct costs. The program is structured around a cooperative agreement requiring several functional components: an Administrative Core, a Workforce Development Core, two to four Scientific Cores, and three Research Projects. A Service and Resource Core is required for Infectious Disease Centers but prohibited for HIV Centers. Applications will be evaluated based on scientific and technical merit, relevance to program priorities, and the availability of funds, with a specific focus on multidisciplinary integration and innovation. Clinical trials are not allowed under this notice. Applicants must maintain active registrations in the System for Award Management and eRA Commons, and all Principal Investigators must have a linked ORCID ID. Required documentation includes a Data Management and Sharing Plan, a Resource Sharing Plan, and letters of institutional support. Strict cybersecurity requirements are in place, including multifactor authentication and a 48-hour incident notification window. The response deadline for this solicitation is May 28, 2027.

National Institutes Of Health

POSTED

DEADLINE

Commercial Suborbital Flight Payload Integration and LaunchThe Commercial Suborbital Flight Payload Integration and Launch subcontract supports NASA Science Mission Directorate projects by providing essential launch vehicles and integration services for prime contractors. The scope of work includes integrating instruments onto launch vehicles, such as the PPSLV, and managing payload configuration and flight performance. To ensure mission success, the contractor is responsible for conducting Continuing Investigation Reviews for safety and product assurance while adhering strictly to NASA safety and mission assurance standards. The primary objectives of this engagement are the successful execution of launches, the recovery of research payloads, and the delivery of critical flight data. This opportunity is categorized under NAICS code 541714 and was posted on October 2, 2026, with a response deadline of November 16, 2026.

Science Mission Directorate

POSTED

DEADLINE

in about 1 month

Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories

Solicitation # 75N98026R00175SB

The National Institutes of Health is issuing a Small Business Sources Sought Notice to identify qualified small businesses capable of providing biobanking, laboratory analytics, and informatics services for NIH biorepositories starting in fiscal year 2028. The scope of work includes the management and secure storage of at least 3.5 million biospecimens, data curation and harmonization, and advanced laboratory capabilities such as high-throughput sequencing and CRISPR/Cas9 gene editing. Additionally, the contractor must provide informatics support to develop and maintain web portals, APIs, and secure cyberinfrastructure compliant with FISMA and NIH requirements. This notice is for market research purposes to determine the availability of small businesses under NAICS code 541714 and does not constitute a solicitation for proposals. Interested firms must submit a detailed capability statement by October 20, 2026, outlining their previous experience, personnel qualifications, and facility capabilities. The government is specifically looking for firms that can maintain a strict chain of custody, adhere to Good Laboratory Practice, and collaborate with NIH Data Centers to support large-scale research studies.

National Institutes Of Health Nida

POSTED

DEADLINE

Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories

Solicitation # 75N98026R00175

The National Institutes of Health is issuing a Sources Sought Notice to identify qualified research and development firms, small businesses, and subcontractors capable of providing biobanking, laboratory analytics, and informatics services for NIH biorepositories starting in fiscal year 2028. The primary objective is to support the operation and potential consolidation of repositories, specifically including the NIDA Center for Genetic Studies and the NIH Brain Development Cohorts Biobank. This is a market research effort to determine the availability of technically capable sources and to inform the government's decision on the appropriate acquisition method and potential small business set-asides. The required scope of work involves the secure storage and tracking of at least 3.5 million biospecimens, comprehensive data curation and management using auditable LIMS, and advanced laboratory capabilities such as high-throughput sequencing and CRISPR/Cas9 gene editing. Additionally, the contractor must provide informatics support to develop and maintain web portals, APIs, and secure cyberinfrastructure compliant with FISMA standards. Interested parties must submit a detailed capability statement, including experience, personnel qualifications, and facility descriptions, to the designated contract specialists by October 20, 2026.

National Institutes Of Health Nida

POSTED

DEADLINE

Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)

Solicitation # ARPA-H-SOL-26-164

The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

in about 2 months

SURPASS Webinar and Proposers' Day Information

Solicitation # ARPA-H-SN-26-164

The Advanced Research Projects Agency for Health (ARPA-H), under the Department of Health and Human Services, has issued Special Notice ARPA-H-SN-26-164 regarding the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program. This initiative aims to modernize clinical research by transforming drug and biologics development into a continuous learning system, with the goal of reducing development timelines from over ten years to fewer than four. The program focuses on creating disease-specific multi-arm platforms that integrate AI-powered operational infrastructure, in silico modeling, and advanced adaptive designs to enable a seamless transition from first-in-patient evaluation to confirmatory assessment. Key outputs include a reusable blueprint for future trials, simulation-based design tools, and continuous inference and adaptation approaches, all aligning with the goals of HHS Operation TrialBlazer. This specific notice serves as an informational announcement and does not constitute a formal solicitation for proposals. It invites interested parties to an informational webinar on October 15, 2026, and a two-day Proposers Day on November 6 and 9, 2026. Potential participants may optionally submit teaming profiles, lightning talk slides, and posters to showcase their expertise. Full program details and formal solicitation requirements are located under solicitation ARPA-H-SOL-26-164. All inquiries are directed to the SURPASS team, with Daria Fedyukina serving as the Technical Point of Contact.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Neuroimaging Analysis and Data CollectionThis subcontract for Neuroimaging Analysis and Data Collection supports National Institutes of Health research projects focused on assessing synaptic integrity and central nervous system outcomes in individuals living with HIV. The scope of work involves performing advanced brain scans using PET or MRI modalities, processing the resulting neuroimaging data, and conducting detailed analyses to identify therapeutic target engagement. The selected provider must ensure strict compliance with 45 CFR Part 46 and obtain necessary IRB approval to conduct the research. Key deliverables include the provision of processed neuroimaging data and comprehensive analytical reports. The opportunity was posted on September 30, 2026, with a response deadline of October 28, 2027, falling under NAICS code 541714.

National Institutes Of Health

POSTED

DEADLINE

in about 1 year

ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening

Solicitation # ARPA-H-SOL-26-165

The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals under solicitation ARPA-H-SOL-26-165 for the Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. This program aims to determine if microgravity in Low Earth Orbit (LEO) accelerates tissue aging across brain, cardiac, uterine, and kidney tissues compared to terrestrial rates. If the Tissue Aging Rate in Space (TARIS) is found to significantly exceed the Tissue Aging Rate on Earth (TAROE), the initiative intends to establish a high-throughput, autonomous drug screening platform in LEO to make biomedical research and development more cost-effective and faster than Earth-based methods. The project is structured into two sequential phases: a 27-month Phase I focused on establishing and validating microphysiological systems (MPS) to quantify aging rates, and a 15-month Phase II dedicated to developing age-related pathology models for pro-regenerative drug testing. Key requirements include the use of MPS or organoids for at least 75 percent of experimental samples, the creation of LEO twin experiments, and the establishment of a contractual partnership with at least one Fortune 100 biopharmaceutical company. The program schedule spans FY27 through FY30 and includes two planned space launches in months 39 and 41. Awards will be granted via multiple Other Transaction (OT) Agreements to the most advantageous proposers, including universities, non-profits, and businesses. Evaluation is based primarily on the innovation and feasibility of the technical approach, the potential to transform biomedicine, and the team's expertise in managing costs and schedules. Proposers must adhere to strict administrative requirements, including the BIOSECURE Act, NIH Genomic Data Sharing policies, and specific research security and cybersecurity disclosures. Full proposals are due by October 7, 2026.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

ARPA-H Emerging Health Innovators (EHI) Initiative

Solicitation # ARPA-H-SOL-26-150

The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, is a mentorship program designed to identify and engage early-career investigators for cutting-edge biomedical, health, and community-engaged research. Eligible principal investigators must be within eight years of completing their first terminal degree. The program focuses on 16 specific topic areas and utilizes a two-step submission process, beginning with an anonymized solution summary due October 30, 2026, followed by full proposals due February 10, 2027. Awards are issued as Other Transaction (OT) agreements with a tentative start date of June 30, 2027. Each award has a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a two-year base period capped at 700,000 dollars and an optional third year capped at 350,000 dollars. Funding is structured around a fixed-price milestone payment schedule, with 12 total quarterly milestones and payments processed through the Payment Management Services (PMS) system. Performance is monitored via monthly one-hour virtual reviews with the ARPA-H program team. Evaluation is based on technical merit, innovativeness, feasibility, and alignment with the ARPA-H mission, with a strong emphasis on risk mitigation and the potential to impact national health research.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Imaging Biomarker Research & AnalysisThis subcontract focuses on the development and testing of imaging-based biomarkers designed to identify pancreatic cancer and its precursor lesions. Working in support of prime contractors on NIH and NCI research projects, the scope of work involves utilizing advanced imaging modalities including MRI, CT, PET, and endoscopic ultrasound to characterize lesions and establish specialized protocols for identifying high-risk patients. Because the work involves human subject research, all activities must be conducted under appropriate IRB approval. The primary deliverables for this engagement consist of finalized imaging biomarker protocols and comprehensive analyzed imaging datasets. This opportunity is categorized under NAICS code 541714 and is associated with the National Institutes of Health within the Department of Health and Human Services. Interested parties must note the response deadline of November 5, 2029, to participate in this research and analysis initiative.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Solicitation # PAR-28-072

The National Institutes of Health National Eye Institute is offering a bi-phasic, milestone-driven award through the Translational Research Program for Therapeutics (PAR-28-072) to accelerate the transition of laboratory research into biological, pharmaceutical, or medical device therapies for visual system diseases. The program is structured into two phases: an R61 phase of up to two years focusing on preliminary data and lead optimization, and an R33 phase of up to four years dedicated to final preclinical development and the filing of an Investigational New Drug or Investigational Device Exemption application with the FDA. The total combined duration of both phases cannot exceed five years. Transition to the R33 phase is contingent upon the administrative assessment of satisfactory completion of SMART milestones, which must include required pre-submission feedback from the FDA. Budgetary limits for direct costs are generally capped at 500,000 dollars per year for the R61 phase and 1,000,000 dollars per year for the R33 phase. Applicants must provide a Target Product Profile, a Gantt chart, and an Intellectual Property Strategy, while ensuring compliance with Good Manufacturing Practices and Good Laboratory Practice standards. Evaluation is based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Eligible applicants, including small businesses and other for-profit organizations, must maintain active registrations in the System for Award Management and eRA Commons, and all principal investigators must have a linked ORCID ID. Awardees are also required to implement cybersecurity incident reporting procedures and an incident response plan in accordance with HHS guidelines.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Institutes of Health, through the National Cancer Institute, is soliciting applications for Research Units (RUs) to join the Pancreatic Cancer Detection Consortium (PCDC). This initiative focuses on the early detection of pancreatic ductal adenocarcinoma (PDAC) and the characterization of precursor lesions to identify high-risk patients. Multi-disciplinary teams will conduct research to identify and test molecular and imaging biomarkers in bodily fluids, develop markers for pancreatic cysts, create screening approaches for high-risk populations, and utilize machine learning for biomarker discovery and validation. Additionally, RUs are required to collect longitudinal biospecimens for a biorepository and engage in collaborative data and resource sharing within the consortium. The award has a five-year project period with a budget limit of 600,000 dollars in direct costs per year. For years two through five, recipients must set aside 100,000 dollars in direct costs annually for trans-PCDC collaborative studies, subject to Steering Committee approval. Key personnel requirements include a minimum commitment of 1.2 person-months per year for the Contact PD/PI and any other PD/PIs. Eligible applicants include for-profit organizations and small businesses, though foreign entities are excluded. Applications are evaluated via the NIH peer review system based on significance, innovation, feasibility, and the expertise of the investigators and their environment. Compliance requirements include maintaining active SAM and eRA Commons registrations and adhering to strict cybersecurity incident reporting timelines of 48 hours. Projects involving clinical trials must be registered on ClinicalTrials.gov and receive NIH approval prior to initiation. Required application materials include SF424 forms, a Resource Sharing Plan, a Data Management and Sharing Plan, and letters of institutional commitment. Awardees must also budget for travel to attend two Steering Committee meetings annually.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Solicitation # PAR-28-072

The National Eye Institute's Translational Research Program (TRP) aims to accelerate the transition of laboratory research into clinical therapeutics for visual system diseases. This program supports the development of pharmaceutical, biological, medical device, or combination therapies through a bi-phasic, milestone-driven award structure. All projects begin with an R61 phase for up to two years to support research with significant preliminary data. Successful projects may transition to an R33 phase for up to four years, focusing on final preclinical development, filing IND/IDE packages with the FDA, and designing future clinical trials. The combined duration of both phases cannot exceed five years. A critical requirement of this program is the establishment of SMART milestones for both phases, which must be specific, measurable, achievable, relevant, and time-bound. Applicants are encouraged to provide contingency plans to address potential delays in meeting these goals. The ultimate objective of the R33 phase is for recipients to either obtain an IND/IDE application or transition the product into clinical practice within the performance period. This solicitation, identified as PAR-28-072, is issued by the National Institutes of Health.

National Eye Institute

POSTED

DEADLINE

in about 3 years

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.

National Cancer Institute

POSTED

DEADLINE

in about 3 years

UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)

Solicitation # ARPA-H-SOL-26-162

The Advanced Research Projects Agency for Health (ARPA-H) has issued Innovative Solutions Opening (ISO) ARPA-H-SOL-26-162 for the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This 18-month, two-phase initiative seeks to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data with quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: TA1, which focuses on the physical systems required to generate and measure quantum observables in biomedical settings, and TA2, which focuses on the computational foundation, including AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements to eligible entities, including universities, non-profit organizations, and businesses. For-profit organizations that exceed the NAICS 541714 SBA size standard of 1,000 employees are required to provide a meaningful cost share. The application process follows a two-stage submission cycle, with Solution Summaries due by late October 2026 and Full Proposals due by December 15, 2026, with a final response deadline of December 16, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on the innovation and feasibility of the technical approach, the expertise of the personnel, the potential to transform biomedicine, and cost reasonableness. Key requirements include compliance with HHS regulations on human stem cells, adherence to cybersecurity standards, and restrictions on gain-of-function research and funding for foreign entities in countries of concern. Awardees will be expected to provide monthly status reports and participate in semi-annual in-person PI review meetings.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

UNifying Imaging with QUantum Entanglement (UNIQUE) Proposers' Day

Solicitation # ARPA-H-SN-26-162

The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures Office, has issued Special Notice ARPA-H-SN-26-162 to announce the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This initiative aims to establish a new biomedical imaging paradigm by utilizing quantum-derived observables, specifically entangled or quantum-correlated 511 keV photon pairs, to reveal disease biology that is currently invisible to existing imaging technologies. The program is divided into two technical areas: an Imaging Core focused on physical systems and quantum-aware detectors, and a second area focused on AI-driven reconstruction and fusion methods to integrate anatomical, functional, molecular, and quantum-derived information. To support this effort, a hybrid Proposers Day is scheduled for October 16, 2026, at 8:30am ET, held at the Executive Conference Center in Arlington, Virginia. This event is designed to provide technical details, promote teaming, and alert the scientific community to an upcoming Innovative Solutions Opening (ISO) that was scheduled for release by September 18, 2026. Interested parties are encouraged to use the provided Lightning Talk Template to showcase their capabilities and teaming goals. While this notice provides program goals and technical direction, it is issued for information and planning purposes and does not constitute a formal solicitation for proposals. The primary point of contact for the program is Program Manager Wilfred Ngwa.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE